Table 1 Baseline characteristics of the included studies
Study ID | Country | Study design | Phase | Groups | N | Tislelizumab dosage | Concomitant chemotherapy | Follow-up (median) |
|---|---|---|---|---|---|---|---|---|
Li et al. 2022 [18] | China | RCT | N/A | TS + CT CT | 33 33 | 200 mg IV OD for 3 weeks in a 3-week cycle for 6 cycles | Mixed 500 mg/m2 pemetrexed disodium with 100 ml of normal saline and mixed 25 mg/m2 of cisplatin with 250 ml of normal saline for 6 cycles | N/A |
Lu et al. 2021 [19] | China | RCT | III | TS + CT CT | 223 111 | 200 mg IV once every 3 weeks for 4 to 6 cycles | Platinum-based chemotherapy (carboplatin AUC 5 or cisplatin 75 mg/m2 in combination with pemetrexed 500 mg/m2), every 3 weeks for 4 to 6 cycles | 9.8 months (95% CI: 9.23–10.38) |
Wang et al. 0.2021 [20] | China | RCT | III | Arm A: TS + CT (PTX + CBP) Arm B: TS + CT (nab PTX + CBP) Arm C: CT (PTX + CBP) | 120 119 121 | 200 mg IV (day 1) every 3 week | Paclitaxel (175 mg/m2 IV, day 1) or nab paclitaxel (100 mg/m2, days 1, 8, and 15); and carboplatin (AUC of 5, day 1), every 3 week | 8.6 months (95% CI: 8.1- 9.0 months) |
Zhou et al. 2022 [21] | Russia, Poland, Mexico, Brazil, New Zealand, China, Turkey, Bulgaria, Lithuania, Slovakia | RCT | III | TS CT | 535 270 | 200 mg IV every 3 weeks | Docetaxel 75 mg/m2 IV, every 3 weeks | TS: 16.0 months (range: 0.3–43.5 months) CT: 10.7 months (range: 0.03–38.3 months) |